Jpmorgan Chase & CO Fulcrum Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.51 Trillion
  • Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,069 shares of FULC stock, worth $156,658. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,069
Previous 18,069 -0.0%
Holding current value
$156,658
Previous $157,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
SELL
$6.34 - $8.84 $1.22 Million - $1.7 Million
-191,824 Reduced 91.39%
18,069 $157,000
Q1 2025

May 12, 2025
BUY
$2.88 - $5.08 $376,626 - $664,326
130,773 Added 165.28%
209,893 $604,000
Q4 2024

Feb 12, 2025
SELL
$2.97 - $4.84 $320,887 - $522,928
-108,043 Reduced 57.73%
79,120 $371,000
Q3 2024

Dec 26, 2024
BUY
$3.18 - $9.74 $490,107 - $1.5 Million
154,122 Added 466.46%
187,163 $668,000
Q3 2024

Nov 08, 2024
BUY
$3.18 - $9.74 $490,107 - $1.5 Million
154,122 Added 466.46%
187,163 $668,000
Q2 2024

Dec 26, 2024
SELL
$5.98 - $9.31 $921,649 - $1.43 Million
-154,122 Reduced 82.35%
33,041 $204,000
Q2 2024

Aug 12, 2024
SELL
$5.98 - $9.31 $752,846 - $1.17 Million
-125,894 Reduced 79.21%
33,041 $204,000
Q1 2024

Dec 26, 2024
SELL
$6.7 - $12.0 $189,127 - $338,736
-28,228 Reduced 15.08%
158,935 $1.5 Million
Q1 2024

May 10, 2024
BUY
$6.7 - $12.0 $988,216 - $1.77 Million
147,495 Added 1289.29%
158,935 $1.5 Million
Q4 2023

Dec 26, 2024
SELL
$3.18 - $6.86 $558,799 - $1.21 Million
-175,723 Reduced 93.89%
11,440 $77,000
Q4 2023

Feb 12, 2024
BUY
$3.18 - $6.86 $1,720 - $3,711
541 Added 4.96%
11,440 $77,000
Q3 2023

Nov 14, 2023
BUY
$3.25 - $6.08 $31,151 - $58,276
9,585 Added 729.45%
10,899 $48,000
Q2 2023

Aug 11, 2023
SELL
$2.26 - $3.8 $427,038 - $718,029
-188,955 Reduced 99.31%
1,314 $4,000
Q1 2023

May 18, 2023
BUY
$2.83 - $13.99 $111,841 - $552,884
39,520 Added 26.22%
190,269 $542,000
Q1 2023

May 11, 2023
SELL
$2.83 - $13.99 $96,041 - $474,778
-33,937 Reduced 18.38%
150,749 $429,000
Q4 2022

Feb 13, 2023
SELL
$5.01 - $8.35 $56,482 - $94,137
-11,274 Reduced 5.75%
184,686 $1.35 Million
Q3 2022

Nov 14, 2022
SELL
$4.92 - $9.1 $10,602 - $19,610
-2,155 Reduced 1.09%
195,960 $1.59 Million
Q2 2022

Aug 11, 2022
SELL
$4.2 - $24.0 $9,538 - $54,504
-2,271 Reduced 1.13%
198,115 $971,000
Q1 2022

May 11, 2022
SELL
$9.96 - $23.65 $24,770 - $58,817
-2,487 Reduced 1.23%
200,386 $4.74 Million
Q4 2021

Feb 10, 2022
BUY
$14.0 - $28.44 $408,044 - $828,912
29,146 Added 16.78%
202,873 $3.59 Million
Q3 2021

Nov 12, 2021
BUY
$7.28 - $30.97 $1.26 Million - $5.38 Million
173,727 New
173,727 $4.9 Million

Others Institutions Holding FULC

# of Institutions
134
Shares Held
55.4M
Call Options Held
176K
Put Options Held
13.5K
View Full List

About Fulcrum Therapeutics, Inc.

FULC Quotes by TradingView
  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $451M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email